Page last updated: 2024-12-06

fendosal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fendosal, also known as N-methyl-N-(2,6-dimethylphenyl)-2-(1H-indol-3-yl)acetamide, is a synthetic compound that has shown promising pharmacological activities. Its synthesis involves a multi-step process starting with indole and 2,6-dimethylaniline. Fendosal exhibits various effects, including anti-inflammatory, analgesic, and antipyretic properties. These effects are attributed to its ability to inhibit the enzyme cyclooxygenase (COX), which plays a role in the production of prostaglandins, inflammatory mediators. Its potential therapeutic applications in pain management and inflammation have led to extensive research efforts to understand its mechanisms of action and optimize its pharmacological profile. Researchers are particularly interested in its selectivity for COX-2, an isoform of COX that is primarily involved in inflammation, as this selectivity could potentially minimize the gastrointestinal side effects associated with non-selective COX inhibitors.'

fendosal: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fendosal : A benzoindole that is 4,5-dihydro-3H-benzo[e]indole in which the nitrogen is substituted by a 3-carboxy-4-hydroxyphenyl group. A non-narcotic analgesic and non-steroidal anti-inflammatory drug, it has greater analgesic and inflammatory responses than aspirin but with less gastrointestinal toxicity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID40821
CHEMBL ID2106146
CHEBI ID135595
SCHEMBL ID24967
MeSH IDM0066428

Synonyms (56)

Synonym
2-hydroxy-5-{2-phenyl-3h,4h,5h-benzo[e]indol-3-yl}benzoic acid
n-(3-carboxy-4-hydroxy)phenylpyrrole
benzoic acid, 5-(4, {5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)-2-hydroxy-}
2-hydroxy-5-(2-phenyl-4,5-dihydro-3h-benzo[e]indol-3-yl)benzoic acid
2-hydroxy-5-(2-phenyl-4,5-dihydrobenzo[e]indol-3-yl)benzoic acid
{5-(4,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)salicylic} acid
hp-129
p 71-0129
nsc-351522
alnovin
fendosal
53597-27-6
5-(4,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)salicylic acid
nsc351522
benzoic acid,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)-2-hydroxy-
hp 129
3-(3-carboxy-4-hydroxyphenyl)-2-phenyl-4,5-dihydro-3h-benz(e)indole
c25h19no3
brn 1665211
nsc 351522
benzoic acid, 5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)-2-hydroxy-
fendosalum [inn-latin]
5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)salicylic acid
5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)-2-hydroxybenzoic acid
fendosal (usan/inn)
D04145
alnovin (tn)
5-(4,5-dihydro-2-phenyl-3h-benzo[e]indol-3-yl)salicylic acid
CHEBI:135595
fendosalum
FT-0650710
A7798
BCP9000007
AKOS015919538
CHEMBL2106146
p-71-0129
5-20-08-00484 (beilstein handbook reference)
unii-9z709558tz
fendosal [usan:inn:ban]
9z709558tz ,
BCP0726000191
fendosal [usan]
fendosal [mi]
fendosal [inn]
SCHEMBL24967
3-(3-carboxy-4-hydroxyphenyl)-4,5-dihydro-2-phenylbenz[e]indole
HAWWPSYXSLJRBO-UHFFFAOYSA-N
DTXSID80201811
BCP03561
AS-35147
fendozal
mfcd00866078
hp 129; nsc 351522; p 71-0129
Q27273407
5-(4,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)-salicylic acid
2-hydroxy-5-(2-phenyl-4,5-dihydro-benzo[e]indol-3-yl)-benzoic acid

Research Excerpts

Effects

ExcerptReferenceRelevance
"Fendosal has a much wider separation of effective and gastric-irritating doses than does aspirin."( Fendosal (HP 129): a potent anti-inflammatory and analgesic compound.
Agnew, MN; Allen, RC; Anderson, VB; Lassman, HB; Novick, WJ; Wilker, JC, 1978
)
2.42
"Fendosal has a much wider separation of effective and gastric-irritating doses than does aspirin."( Fendosal (HP 129): a potent anti-inflammatory and analgesic compound.
Agnew, MN; Allen, RC; Anderson, VB; Lassman, HB; Novick, WJ; Wilker, JC, 1978
)
2.42

Bioavailability

ExcerptReferenceRelevance
"Fendosal (200 mg) was given orally to each of two separate groups of twelve healthy male volunteers on separate occasions to assess the influence of food or antacid on the bioavailability of fendosal."( The effect of food and antacid on the absorption of fendosal.
Puri, SK; Velagapudi, RB; Wills, RJ; Yakatan, GJ,
)
1.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyrrolesAn azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton.
benzoindole
monohydroxybenzoic acidAny hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1144896Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 30 mins prior to 1%, sc carrageenan challenge measured after 3 hrs1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Carboxyarylindoles as nonsteroidal antiinflammatory agents.
AID1144899Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 120 mins prior to 1%, sc carrageenan challenge measured after 3 hrs1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Carboxyarylindoles as nonsteroidal antiinflammatory agents.
AID1131966Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 30 mins prior challenge measured after 3 hrs relative to placebo-control1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis of carboxyarylindoles and benzofurans as nonsteroidal antiinflammatory agents.
AID1144897Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 30 mins prior to 1%, sc carrageenan challenge measured after 3 hrs1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Carboxyarylindoles as nonsteroidal antiinflammatory agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.13 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (30.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (70.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]